Clinical Trials Sponsored by HG&H Pharmaceuticals

Total 90 results

Northumbria University
HG&H Pharmaceuticals

Recruiting

Psychological Effects of 8 Weeks Supplementation With Sceletium Tortuosum Extract (ZEMBRIN)

Stress, Psychological | Cognitive Change

United Kingdom
H. Lundbeck A/S
Solvay Pharmaceuticals

Terminated

Bifeprunox Extension to Extension Study in Patients With Schizophrenia

Schizophrenia

Italy
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Terminated

Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Major Depressive Disorder

United States
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (STARBRIGHT)

Alzheimer's Disease

United States, Australia, Brazil, Czechia, Germany, Israel, Korea, Republic of, Mexico, Serbia, Singapore, Slovakia, Spain, Switzerland, Turkey, United Kingdom
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Major Depressive Disorder

Finland, Sweden, Estonia, Bulgaria, United States, Canada, Germany, Korea, Republic of, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Ukraine, United Kingdom
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S

Completed

A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects

Alcohol Dependence

Japan
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole in Patients With Schizophrenia

Schizophrenia

Serbia, Estonia, United States, Poland, Romania, Russian Federation, Slovakia, Ukraine
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole in Patients With Acute Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Europe Ltd
H. Lundbeck A/S

Unknown

Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia

Schizophrenia

Spain, Italy, France, Germany
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Terminated

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil (STARSHINE)

Alzheimer's Disease

Germany, United States, Argentina, Belgium, Bulgaria, Canada, Chile, Czechia, Denmark, France, Italy, Poland, Romania, South Africa, Spain, Ukraine
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

Schizophrenia

United States
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Terminated

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

PTSD | Post-traumatic Stress Disorder

Finland, Estonia, South Africa, Poland, United States, France, Italy, Serbia, Sweden
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S

Completed

A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence

Alcohol Dependence

Japan
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)

Alcohol Dependence

Japan
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil (STARBEAM)

Alzheimer's Disease

United States, Argentina, Brazil, Canada, Croatia, Czechia, Estonia, Finland, France, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Poland, Portugal, Taiwan, United Kingdom, Ireland
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole Once-monthly in Patients With Schizophrenia

Schizophrenia

United States
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Withdrawn

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone (TAILWIND)

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Active, not recruiting

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer's Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer Dementia | Agitation Associated With Alzheimer's Dementia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Active, not recruiting

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Irritability Associated With Autism Spectrum Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Withdrawn

Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

Major Depressive Disorder (MDD)
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

Spain, United States, Germany, Croatia, Serbia, Russian Federation, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.

Bipolar I Disorder | Acute Mania

United States, Serbia, Bulgaria, Croatia, Poland, Ukraine
Zhejiang Kanglaite Pharmaceutical Co.Ltd
H & J CRO International, Inc.

Unknown

A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia

Cancer Cachexia

China
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder

Bipolar I Disorder | Manic Episode

United States, Croatia, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder | Manic Episode

Serbia, United States, Bulgaria, Poland
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

Nervous System Diseases | Mental Disorder | Alzheimer's Type | Agitation Associated With Alzheimer's Disease

United States, Germany, France, Bulgaria, Spain, Slovenia, Croatia, Serbia, Russian Federation, Ukraine, Canada, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (Anchor)

Irritability Associated With Autism Spectrum Disorder (ASD)

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Stress Disorders, Post-Traumatic

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

France, United States, Bulgaria, Slovenia, United Kingdom, Russian Federation, Ukraine, Finland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder (ATLAS)

Bipolar I

United States, France, Romania, Poland, Canada, Hungary, Japan, Korea, Republic of, Malaysia, Taiwan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

Bipolar I Disorder

United States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Germany, Poland, Hungary, Slovakia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

ADHD | Conduct Disorder | Oppositional Defiant Disorder | Autism | Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Terminated

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Nervous System Diseases | Schizophrenia | Mental Disorder

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Recruiting

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Myelodysplastic Syndromes

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals

Active, not recruiting

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Hormone Receptor-positive Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Active, not recruiting

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals

Terminated

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Cutaneous Squamous Cell Carcinoma of the Head and Neck | Cutaneous Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Completed

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Completed

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

Pancreatic Cancer

United States

Clinical Trials Sponsored by HG&H Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations